Navidea Biopharmaceuticals Inc

ASE:NAVB   3:59:52 PM EDT
-0.03 (-1.54%)
Products

Navidea Biopharmaceuticals Announces End-Of-Phase 2 Type B Meeting Request Granted By The FDA To Discuss Ongoing Clinical Program In Rheumatoid Arthritis

Published: 07/15/2021 11:41 GMT
Navidea Biopharmaceuticals Inc (NAVB) - Navidea Biopharmaceuticals Announces End-of-phase 2 Type B Meeting Request Granted by the FDA to Discuss Ongoing Clinical Program in Rheumatoid Arthritis.
Navidea Biopharmaceuticals Inc - Meeting Will Take Place on September 1, 2021, Via Conference Call.
Navidea Biopharmaceuticals Inc - Meeting With FDA Will Be Centered on Discussion of Results From Company's Completed Phase 2b Nav3-31 Study.